8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): July 30, 2014

Illumina, Inc.

__________________________________________

(Exact name of registrant as specified in its charter)

Delaware	001-35406	33-0804655
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)
5200 Illumina Way, San Diego, California		92122
_________________________________ (Address of principal executive offices)		___________ (Zip Code)

Registrant’s telephone number, including area code: (858) 202-4500

______________________________________________

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective as of July 30, 2014, the Board of Directors (the "Board") of Illumina, Inc. (the "Company") increased the size of the Board from 10 to 11 members and elected Jeffrey T. Huber to serve on the Board.  Mr. Huber has been assigned to serve in the class of directors currently including Francis deSouza, Gerald Möller, and David Walt, and, consistent with the Company’s Corporate Governance Guidelines, Mr. Huber will stand for election by the Company’s stockholders at the Company’s 2015 annual meeting of stockholders to serve for a one-year term commencing with such meeting.  There is no arrangement or understanding between Mr. Huber and any other person pursuant to which he was selected as a director.  In addition, Mr. Huber is not a party to any transaction with the Company reportable under Item 404(a) of Regulation S-K under the Securities Act of 1933.  Mr. Huber will participate in the non-employee director compensation programs described under "Director Compensation" in the Company's proxy statement filed on April 11, 2014.  A copy of the Company's press release announcing Mr. Huber’s appointment is filed as Exhibit 99.1 to this Form 8-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ILLUMINA, INC.
Date: July 31, 2014	By:	/s/ Charles E. Dadswell
		Name: Charles E. Dadswell
		Title: Senior Vice President & General Counsel

EX-99.1

Illumina Appoints Jeff Huber to its Board of Directors

SAN DIEGO - (BUSINESS WIRE) - July 31, 2014 - Illumina, Inc. (NASDAQ:ILMN) today announced that Jeff Huber has joined the company’s Board of Directors. Mr. Huber is Senior Vice President at Google Inc. where he works at Google[x].

Mr. Huber joined Google in 2003 and led development for Google Maps (2011-2013), Google Apps (2005-2010), and Google Ads (2003-2011). Prior to Google, Mr. Huber was Vice President of Architecture and Systems Development at eBay Inc., where he implemented eBay’s massively scalable technology foundation, and Senior Vice President of Engineering at Excite@Home, where he led consumer product and infrastructure development. Mr. Huber is also a member of the board of directors and audit committee of Electronic Arts Inc.

“We are pleased to welcome Jeff to the Illumina Board and to leverage his expertise as we work to make genomic data accessible to the widest possible community of researchers and clinicians,” said Jay Flatley, Illumina’s CEO. “As a pioneer in big data analytics and highly scalable informatics, Jeff’s perspective will greatly benefit our efforts to harness massive amounts of genomic data to accelerate the discovery of new associations between the human genome and disease.”

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Source: Illumina, Inc.

Illumina, Inc.

Investors:

Rebecca Chambers

Investor Relations

858-255-5243

rchambers@illumina.com

or

Media:

Jennifer Temple

Public Relations

858-882-6822

pr@illumina.com